Skip to main navigation Skip to search Skip to main content

Targeting hypoxia-inducible factors: therapeutic opportunities and challenges

  • Xiaoyi Yuan
  • , Wei Ruan
  • , Bentley Bobrow
  • , Peter Carmeliet
  • , Holger K. Eltzschig
  • University of Texas Health Science Center at Houston
  • Central South University
  • KU Leuven
  • Aarhus University
  • Outcomes Research Consortium

Research output: Contribution to journal › Review article › peer-review

177 Scopus citations

Abstract

Hypoxia-inducible factors (HIFs) are highly conserved transcription factors that are crucial for adaptation of metazoans to limited oxygen availability. Recently, HIF activation and inhibition have emerged as therapeutic targets in various human diseases. Pharmacologically desirable effects of HIF activation include erythropoiesis stimulation, cellular metabolism optimization during hypoxia and adaptive responses during ischaemia and inflammation. By contrast, HIF inhibition has been explored as a therapy for various cancers, retinal neovascularization and pulmonary hypertension. This Review discusses the biochemical mechanisms that control HIF stabilization and the molecular strategies that can be exploited pharmacologically to activate or inhibit HIFs. In addition, we examine medical conditions that benefit from targeting HIFs, the potential side effects of HIF activation or inhibition and future challenges in this field.

Original languageEnglish
Pages (from-to)175-200
Number of pages26
JournalNature Reviews Drug Discovery
Volume23
Issue number3
DOIs
StatePublished - Mar 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Targeting hypoxia-inducible factors: therapeutic opportunities and challenges'. Together they form a unique fingerprint.

Cite this